Skip to main content
. 2020 Jul 1;7(3):112–117. doi: 10.5152/eurjrheum.2020.19132

Table 2.

Comorbid conditions in patients with pSS.

Comorbidities, % C3 complement levels C4 complement levels


Normal (n=85) Low (n=9) p Normal (n=81) Low (n=13) p
Hypertension 37.7 44.4 0.728 40.7 23.1 0.224
Type 2 diabetes mellitus 12.9 0.0 0.592 13.6 0.0 0.352
Dyslipidemia 36.5 11.1 0.160 38.3 7.7 0.054
Overweight/obesity (BMI ≥25.0) 66.2 55.6 0.713 65.7 61.5 0.761
Coronary artery disease 4.7 0.0 0.999 4.9 0.0 0.999
Hypothyroidism 32.9 44.4 0.484 34.6 30.8 0.999
Asthma 7.1 33.3 0.039 7.4 23.1 0.107
Osteoarthritis 42.4 44.4 0.999 45.7 23.1 0.126
Osteoporosis 12.9 33.3 0.129 16.1 7.7 0.683
Fibromyalgia 18.8 0.0 0.349 19.8 0.0 0.115
Depression 25.9 33.3 0.696 25.9 30.8 0.740
Headaches 5.9 11.1 0.463 6.2 7.7 0.999
Peptic ulcer disease/gastritis 22.4 0.0 0.196 21.0 15.4 0.999
Infections (any cause) 27.1 33.3 0.704 25.9 38.5 0.339
Neoplasia 7.1 0.0 0.999 4.9 16.7 0.171

BMI: body mass index; pSS: primary Sjögren’s syndrome.